The trial did not obtain pharmacokinetic data for the cannabinoid interventions or concomitant medications. A prescribed dose therefore cannot be presented as a measured systemic exposure in these participants.
Dose and concentration were separate questions
The study compared whole-plant CBD/THC extract, purified CBD plus THC and placebo. Both active products used the same nominal 20:1 CBD:THC ratio, with dosing adjusted by protocol and tolerability. The authors explicitly identified absent pharmacokinetic data as a limitation.
Existing stable treatments continued, but the study did not quantify their concentration-time profiles or cannabinoid-related changes in those profiles.
Unmeasured mechanisms remain hypotheses
The study cannot establish that a responder had a particular CBD level, that a nonresponder failed to absorb the medicine or that a drug interaction caused an adverse event. The same prescribed ratio also does not demonstrate identical biological exposure across participants or formulations. These would require measurements not provided here.
Retain the observed clinical pattern
Clinical outcomes were mixed: one co-primary behavioral measure favored whole-plant extract while another did not distinguish treatment from placebo. Missing pharmacokinetic information does not erase those observations or explain them by assumption. It limits exposure-response and mechanism claims, especially efforts to derive an individual target concentration from the trial.
Related reading: limits of proposed CBD mechanisms.
Research cited
Aran and colleagues (2021). Cannabinoid treatment for autism: a proof-of-concept randomized trial. DOI: 10.1186/s13229-021-00420-2.
Leave a Reply